Lactobacillus rhamnosus and application thereof

By using Lactobacillus rhamnosus JY027 and its extracellular polysaccharide complex, the problem of large drug side effects in existing technologies has been solved, achieving effective relief and improvement of type 2 diabetes mellitus complicated with hyperuricemia, and providing a safe treatment option.

CN117904000BActive Publication Date: 2024-11-29NORTHEAST AGRICULTURAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410238340.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-03
Publication Date
2024-11-29
Estimated Expiration
2044-03-03

AI Technical Summary

Technical Problem

Existing technologies for alleviating type 2 diabetes mellitus complicated by hyperuricemia have problems such as significant drug side effects and difficulty for patients to control their diet in the long term, and there is a lack of effective alternatives.

Method used

By using Lactobacillus rhamnosus JY027 and its extracellular polysaccharide complex, a drug to alleviate hyperuricemia in type 2 diabetes was prepared. The synergistic effect of probiotics and extracellular polysaccharides was utilized to improve gut health, reduce serum and urine uric acid levels, and regulate lipid metabolism.

Benefits of technology

It significantly reduced serum uric acid, urinary uric acid, and xanthine oxidase levels in the liver of mice with type 2 diabetes and hyperuricemia, improved glucose and lipid metabolism, and provides potential applications for functional food additives.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117904000B_ABST
    Figure CN117904000B_ABST
Patent Text Reader

Abstract

The present invention discloses a Lactobacillus rhamnosus and its application, and belongs to the field of microbial technology. Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus) JY027 is deposited in Guangdong Microbial Culture Collection Center, with a deposit date of November 21, 2022, and a deposit number of GDMCC NO: 62991. Compared with Lactobacillus rhamnosus alone, Lactobacillus rhamnosus JY027 and its extracellular polysaccharide of the present invention have a significant reduction trend in uric acid in the serum, uric acid in urine and xanthine oxidase content in the liver of mice. Compared with Lactobacillus rhamnosus extracellular polysaccharide alone, it significantly reduces the levels of fasting blood glucose, total cholesterol, triglycerides, and low-density lipoprotein-cholesterol in mice, while significantly increasing high-density lipoprotein-cholesterol, so the present invention can be used to alleviate / treat the situation of diabetes complicated with hyperuricemia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a lactobacillus rhamnosus and an application thereof, in particular to a lactobacillus rhamnosus JY027 and an extracellular polysaccharide and a complex thereof and an application thereof in preparing a drug for alleviating type 2 diabetes complicated with hyperuricemia, and belongs to the technical field of microorganisms. Background Art

[0002] Nowadays, changes in people's dietary structure have led to an increase in uric acid content in the human body, resulting in the frequent occurrence of hyperuricemia. Hyperuricemia is a chronic disease caused by purine metabolism disorder in the body. It is not only the biochemical basis for the onset of gout, but also easily leads to the occurrence of many chronic diseases such as diabetes, atherosclerosis, obesity, uric acid nephropathy, etc. Type 2 diabetes is the most common type of diabetes, characterized by elevated blood sugar levels. Type 2 diabetes is associated with insulin resistance and relative insulin deficiency. Insulin is an important hormone responsible for helping the body's cells absorb glucose. Insulin resistance means that the body's cells respond less to insulin, leading to increased blood sugar levels. The connection between hyperuricemia and type 2 diabetes is bidirectional, and the two affect each other and aggravate the condition. They are both components of metabolic syndrome, factors that increase the risk of cardiovascular disease, including high blood pressure, abdominal obesity, high blood sugar and abnormal lipid metabolism, which pose a serious threat to human life and health.

[0003] High uric acid levels in the body may be associated with insulin resistance, which is one of the core mechanisms of type 2 diabetes. Studies have shown that uric acid may directly affect the signaling pathway of insulin, thereby reducing its effectiveness and exacerbating or promoting the development of diabetes. High uric acid levels are also associated with increased systemic inflammation, which is a key factor in the development of type 2 diabetes. Uric acid crystals can deposit in the body, triggering an inflammatory response, further exacerbating insulin resistance. In addition, hyperuricemia is associated with endothelial dysfunction, which is an important precursor to cardiovascular complications in patients with type 2 diabetes. Similarly, patients with type 2 diabetes often have insulin resistance, which not only affects glucose metabolism but may also affect the excretion of uric acid. Studies have shown that insulin resistance may lead to reduced uric acid excretion, thereby increasing blood uric acid levels. Diabetes can also lead to kidney disease, including kidney damage such as diabetic nephropathy. Weakened kidney function reduces its ability to clear uric acid, leading to hyperuricemia.

[0004] At present, the prevention and treatment measures for hyperuricemia and type 2 diabetes mainly include drug treatment and reducing the intake of high-purine and high-sugar diets. However, all drugs have certain side effects and cannot be widely used. In addition, patients need to control their diet while taking drugs, which will lead to nutritional imbalance in patients. Since the current treatment methods require patients to control their diet and the side effects of drugs are large, and most patients cannot achieve long-term control. Therefore, exploring new methods to alleviate hyperuricemia and type 2 diabetes has become a hot topic of research in all walks of life.

[0005] Probiotics are active microorganisms that colonize the human body and can benefit the host's health. Probiotics can not only promote intestinal health, but also have beneficial functions such as enhancing the immune system, promoting cardiovascular health and anti-allergy. Exopolysaccharides (EPS) are a class of high-molecular polysaccharides produced by probiotics, which are secreted into the extracellular environment. EPS has a variety of biological activities and has a positive impact on human health, including improving intestinal health, enhancing the immune system, anti-inflammatory, and antioxidant effects. Probiotics and exopolysaccharides can work synergistically, among which probiotics can help maintain the balance of intestinal flora, while EPS can resist pathogens by forming a protective film, reduce intestinal inflammation, and promote the repair of intestinal mucosa, thereby improving intestinal health.

[0006] In summary, the use of probiotics and the extracellular polysaccharides they produce can work synergistically, replace drugs and control patients' diet to relieve type 2 diabetes complicated by hyperuricemia, and effectively reduce the negative effects of these two on patients.

[0007] Therefore, there is an urgent need for an application of Lactobacillus rhamnosus and its extracellular polysaccharide that can effectively alleviate hyperuricemia complicated by type 2 diabetes. Summary of the invention

[0008] The purpose of the present invention is to provide a Lactobacillus rhamnosus JY027.

[0009] At the same time, the purpose of the present invention is to provide an extracellular polysaccharide of Lactobacillus rhamnosus JY027.

[0010] At the same time, the purpose of the present invention is to provide a method for preparing the extracellular polysaccharide of Lactobacillus rhamnosus JY027.

[0011] Meanwhile, the purpose of the present invention is to provide a complex containing extracellular polysaccharide of Lactobacillus rhamnosus JY027, which has the effect of alleviating hyperuricemia complicated by type 2 diabetes.

[0012] At the same time, the purpose of the present invention is to provide an application of a complex containing Lactobacillus rhamnosus JY027 and its extracellular polysaccharide in the preparation of a drug for alleviating type 2 diabetes complicated with hyperuricemia.

[0013] At the same time, the purpose of the present invention is to provide an application of a complex containing Lactobacillus rhamnosus JY027 and its extracellular polysaccharide in the preparation of a drug for treating type 2 diabetes complicated with hyperuricemia.

[0014] In order to solve the above technical problems, the technical solution adopted by the present invention is:

[0015] Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus) JY027, the Lactobacillus rhamnosus JY027 is preserved in Guangdong Provincial Microbiological Culture Collection Center, Guangzhou, the preservation date is November 21, 2022, and the preservation number is GDMCCNO: 62991.

[0016] The preparation method of the extracellular polysaccharide of Lactobacillus rhamnosus JY027 comprises the following steps: inoculating the activated Lactobacillus rhamnosus JY027 in a sterile MRS liquid culture medium at a ratio of 5%, culturing at 37°C under anaerobic conditions for 24 hours, centrifuging the culture solution at 10000g for 10 minutes at 4°C, discarding bacterial precipitates, taking the supernatant fermentation solution, adding 80% trichloroacetic acid solution to make the final concentration of 4%, and standing at 4°C for 12 hours; centrifuging to remove protein precipitates; concentrating the supernatant after centrifugation to 20% of the original volume by rotary evaporation, then adding 3 times cooled anhydrous ethanol to a final concentration of 75%, standing at 4°C for 12 hours, centrifuging at 10000g for 10 minutes to collect the precipitate, and adding an appropriate amount of deionized water to dissolve the precipitate; dialyzing the solution with a dialysis bag of 8000-13000Da for 72 hours, changing the deionized water every 8 hours during the period; vacuum freeze drying after the dialysis is completed, and finally obtaining EPS.

[0017] The purity of the extracellular polysaccharide, EPS, of Lactobacillus rhamnosus JY027 is above 80%.

[0018] A complex containing extracellular polysaccharide of Lactobacillus rhamnosus JY027, consisting of Lactobacillus rhamnosus JY027 and EPS, wherein the number of viable bacteria of Lactobacillus rhamnosus JY027 is not less than 10 9 cfu / mL; the volume mass ratio of Lactobacillus rhamnosus JY027 and EPS is 0.2mL:150mg.

[0019] Application of the complex of the present invention in preparing a drug for alleviating type 2 diabetes complicated with hyperuricemia.

[0020] The composite of the present invention is used in preparing a drug for treating type 2 diabetes complicated with hyperuricemia.

[0021] The invention discloses an application of the Lactobacillus rhamnosus JY027 in preparing a drug for alleviating type 2 diabetes complicated with hyperuricemia.

[0022] The invention discloses an application of the Lactobacillus rhamnosus JY027 in preparing a medicine for treating type 2 diabetes complicated with hyperuricemia.

[0023] The present invention has the following beneficial effects:

[0024] The Lactobacillus rhamnosus and the extracellular polysaccharide thereof provided by the present invention can reduce the content of uric acid in the serum, uric acid in the urine and xanthine oxidase (XOD) in the liver of mice with type 2 diabetes complicated by hyperuricemia.

[0025] The Lactobacillus rhamnosus and the extracellular polysaccharide thereof provided by the present invention can reduce the fasting blood sugar, total cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol (HDL-C) contents of mice with type 2 diabetes complicated with hyperuricemia.

[0026] The Lactobacillus rhamnosus and the extracellular polysaccharide thereof provided by the present invention can alleviate hyperuricemia complicated by type 2 diabetes in mice, and can be used as a functional food additive for human consumption.

[0027] The Lactobacillus rhamnosus JY027 and its extracellular polysaccharide provided by the present invention have a significant trend of reducing uric acid in serum, uric acid in urine and xanthine oxidase content in liver of mice compared with Lactobacillus rhamnosus alone. Compared with Lactobacillus rhamnosus extracellular polysaccharide alone, it significantly reduces the fasting blood sugar, total cholesterol, triglyceride, low-density lipoprotein-cholesterol levels of mice and significantly increases high-density lipoprotein-cholesterol, so the Lactobacillus rhamnosus JY027 and its extracellular polysaccharide can be used to alleviate / treat the situation of diabetes complicated with hyperuricemia. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 This is a graph showing the changes in serum uric acid content in each group of mice in the present invention;

[0029] Figure 2 The figure is a graph showing the change of uric acid content in urine of each group of mice in the present invention;

[0030] Figure 3 The graph is a result of the changes in the XOD content in the liver of each group of mice in the present invention;

[0031] Figure 4 This is a graph showing the changes in fasting blood glucose levels in each group of mice in the present invention;

[0032] Figure 5 This is a graph showing the changes in TC content in the serum of each group of mice in the present invention;

[0033] Figure 6 This is a graph showing the changes in serum TG content in each group of mice in the present invention;

[0034] Figure 7 This is a graph showing the changes in serum LDL-C levels in each group of mice in the present invention;

[0035] Figure 8 This is a graph showing the changes in HDL-C levels in the serum of each group of mice in the present invention. DETAILED DESCRIPTION

[0036] The present invention will be further described below in conjunction with the accompanying drawings.

[0037]

[0038] The screening, identification, cultivation, observation and preservation of Lactobacillus rhamnosus JY027 are as follows:

[0039] 1. Screening

[0040] Take 1g of traditional fermented dairy products from Tibet, spread it on MRS solid culture medium (including rapid screening) after gradient dilution, and culture it in an anaerobic environment at 37℃ for 48h, observe and record the colony morphology; pick white colonies with moist surface and protrusions, streak them on MRS solid culture medium, and purify and culture them under anaerobic conditions at 37℃. Repeat this operation 3 times to obtain purified single colonies; pick single colonies and streak them on MRS solid culture medium, and culture them anaerobically at 37℃ for 48h.

[0041] 2. Identification

[0042] The genome of the strain obtained by screening was extracted, and the 16S rDNA of the strain was amplified and sequenced (the nucleotide sequence of the amplified 16S rDNA is shown in SEQ ID NO.1). The obtained sequence was compared with the nucleic acid sequence in NCBI-Blast, and the results showed that the strain was Lactobacillus rhamnosus, and was named Lactobacillus rhamnosus JY027.

[0043] The primers used for 16S rDNA amplification are as follows:

[0044] 27F upstream primer: 5′-AGTCTCTGATCATGCCTCAG-3′;

[0045] 1492R downstream primer: 5′-AAGGAGGTGCTCCAGCC-3′;

[0046] The 16S rDNA amplification procedure is as follows:

[0047] 95°C for 5 min; 35 cycles (95°C for 30 s; 55°C for 30 s; 72°C for 2 min); 72°C for 10 min.

[0048] 4. Save

[0049] A single colony of Lactobacillus rhamnosus JY027 was picked and inoculated into MRS liquid culture medium, and cultured at 37°C under anaerobic conditions for 17 hours to obtain a bacterial solution; sterilized 80% (v / v) glycerol was added to the obtained bacterial solution and mixed well, and then stored in a glycerol tube at -80°C. At the same time, Lactobacillus rhamnosus was deposited in Guangdong Provincial Microbiological Culture Collection Center, Guangzhou, with a preservation date of November 21, 2022, and a preservation number of GDMCC NO: 62991.

[0050] (1) Extraction of extracellular polysaccharides from Lactobacillus rhamnosus JY027

[0051] The activated Lactobacillus rhamnosus JY027 was inoculated into sterile MRS liquid culture medium at a ratio of 5%, and cultured at 37°C under anaerobic conditions for 24 hours. The culture solution was centrifuged at 10000g for 10 minutes at 4°C, the bacterial precipitate was discarded, and the supernatant fermentation solution was taken. 80% trichloroacetic acid solution was added to make the final concentration of 4%, and it was allowed to stand at 4°C for 12 hours. The protein precipitate was removed by centrifugation. The supernatant after centrifugation was concentrated to 20% of the original volume by rotary evaporation, and then 3 times the volume of cooled anhydrous ethanol was added to a final concentration of 75%, and it was allowed to stand at 4°C for 12 hours. The precipitate was collected by centrifugation at 10000g for 10 minutes, and an appropriate amount of deionized water was added to dissolve the precipitate. The solution was dialyzed with a 8000-13000Da dialysis bag for 72 hours, and the deionized water was changed every 8 hours. After the dialysis was completed, vacuum freeze drying was performed to obtain EPS. The purity of the extracted polysaccharide was determined by the phenol-sulfuric acid method to ensure that the purity was above 80% for in vivo experiments.

[0052] (2) Establishment of animal model

[0053] The experiment used 50 7-8 week old male C57BL / 6 mice, weighing 25-30g. After 1 week of adaptive feeding with normal feed and free drinking water, they were randomly divided into 5 groups (10 in each group): normal group (NC), hyperuricemia complicated with diabetes group (HUA+DM), Lactobacillus rhamnosus JY027 group (LR), Lactobacillus rhamnosus JY027 extracellular polysaccharide group (EPS), and bacterial sugar complex group (LR+EPS). Except for the normal group, the other groups were fed with high-fat and high-sugar feed for 4 weeks. Before modeling, fasting but not water was performed for 12h, and streptozotocin 150μg / g was injected intraperitoneally. After 72h, the random blood glucose in the tail vein of the mice was measured, and the model was successful if it was greater than 11.1mmol / L. After the blood sugar of the successfully modeled mice was stabilized for 1 week, they were gavaged with 500 mg / kg·d hypoxanthine and injected with 100 mg / kg·d potassium oxonate for 4 weeks, starting from the 8th day of gavage with hypoxanthine and continuing for 21 days. 9cfu / mL of Lactobacillus rhamnosus JY027, 150mg / kg.bw of EPS and 0.2mL of 10 9 cfu / mL Lactobacillus rhamnosus JY027 and 150mg / kg.bw EPS complex.

[0054] (3) Effects of bacterial sugar complex on hyperuricemia in mice

[0055] Before the end of the experiment, the mice were fasted for 12 hours, and then blood was collected from the eyeballs. The blood was centrifuged to collect mouse serum for the determination of uric acid content in mouse serum. The collected mouse serum was used to detect the uric acid level in serum according to the instructions of the kit. One day before the end of the experiment, the mouse urine was collected for the determination of uric acid content in mouse urine. The collected mouse urine was used to detect the uric acid level in urine according to the instructions of the kit. After the end of the experiment, the mice were anesthetized and killed by cervical dislocation. The body surface was disinfected and then dissected. The mouse liver was collected and placed in liquid nitrogen for quick freezing and stored at -80°C. The mouse liver was added to PBS buffer with pH = 7.4, liver mass: PBS solution = 1:9 (m / v), ice bath homogenized, centrifuged at 3100g for 10 minutes, and the supernatant was collected. The XOD content in the mouse liver was detected according to the instructions of the kit.

[0056] Results: Figure 1-Figure 3 As shown in the figure, compared with the NC group, the serum uric acid, urine uric acid and XOD in the liver of the HUA+DM group mice were increased to varying degrees (p<0.05). However, after oral administration of Lactobacillus rhamnosus JY027 and extracellular polysaccharides, the contents of each group were reduced to varying degrees compared with the HUA+DM group. The reduction of the three indicators in the LR group was more obvious than that of EPS alone, indicating that the strain has a certain uric acid-lowering function. After oral administration of bacteria-sugar compound, the reduction effect of the three indicators of serum uric acid, urine uric acid and liver XOD in mice was the most significant (p<0.05), indicating that the bacteria-sugar compound played a synergistic role, making the strain's uric acid-lowering effect better.

[0057] (4) Effects of bacterial sugar complex on diabetes in mice

[0058] Before the end of the experiment, the mice were fasted for 12 h, and then blood was collected from the eyeballs. The blood was centrifuged to collect mouse serum for the determination of mouse blood glucose, total cholesterol (TC), triglycerides (TG), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol (HDL-C) levels.

[0059] Results: Figure 4-Figure 8As shown in the figure, compared with the NC group, the fasting blood glucose, TC, TG, and LDL-C levels of mice in the HUA+DM group increased to varying degrees, while the HDL-C value decreased significantly (p<0.05). However, after oral administration of Lactobacillus rhamnosus JY027 and extracellular polysaccharides, the contents of each group decreased (increased) to varying degrees compared with the HUA+DM group. The relief of several indicators in the EPS group was more obvious than that of the strain alone, indicating that the polysaccharide has a certain hypoglycemic function. After oral administration of bacteria-sugar compound, the relief effect of blood glucose and other indicators of mice was the most significant (p<0.05), indicating that the bacteria-sugar compound played a synergistic role, making the strain's hypoglycemic effect better.

[0060] In summary, the Lactobacillus rhamnosus JY027 and its extracellular polysaccharide of the present invention can alleviate and treat type 2 diabetes complicated with hyperuricemia.

[0061] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus )JY027, It is characterized in that The Lactobacillus rhamnosus is deposited in Guangdong Provincial Microbiological Culture Collection Center, Guangzhou, with a preservation date of November 21, 2022 and a preservation number of GDMCC NO: 62991.

2. The method for preparing the extracellular polysaccharide of Lactobacillus rhamnosus JY027 according to claim 1, It is characterized in that The method comprises the following steps: inoculating activated lactobacillus rhamnosus JY027 into a sterile MRS liquid culture medium at a ratio of 5%, culturing at 37°C under anaerobic conditions for 24 hours, centrifuging the culture solution at 10000 g for 10 minutes at 4°C, discarding bacterial precipitates, taking the supernatant fermentation solution, adding 80% trichloroacetic acid solution to make the final concentration of 4%, and standing at 4°C for 12 hours; centrifuging to remove protein precipitates; concentrating the supernatant after centrifugation to 20% of the original volume by rotary evaporation, then adding 3 times the volume of cooled anhydrous ethanol to a final concentration of 75%, standing at 4°C for 12 hours, centrifuging at 10000 g for 10 minutes to collect the precipitate, and adding an appropriate amount of deionized water to dissolve the precipitate; dialyzing the solution with a dialysis bag of 8000-13000 Da for 72 hours, changing the deionized water every 8 hours during the period; and performing vacuum freeze drying after the dialysis is completed to obtain EPS.

3. A complex containing the exopolysaccharide of Lactobacillus rhamnosus JY027 obtained by the method for producing the exopolysaccharide of Lactobacillus rhamnosus JY027 according to claim 2, It is characterized in that It is composed of Lactobacillus rhamnosus JY027 and EPS, and the number of viable bacteria of Lactobacillus rhamnosus JY027 is not less than 10 9 cfu / mL; the volume mass ratio of Lactobacillus rhamnosus JY027 and EPS is 0.2mL:150mg.

Citation Information

Patent Citations

  • Lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia

    CN112574917A

  • Lactobacillus rhamnosus JL-1 for relieving hypeluricemia as well as metaplasm and application of lactobacillus rhamnosus JL-1

    CN116836889A